Literature DB >> 32813090

Acute and subacute oral administration of mycotoxin deoxynivalenol exacerbates the pro-inflammatory and pro-pruritic responses in a mouse model of allergic dermatitis.

Ryota Aihara1, Toa Ookawara1, Ai Morimoto1, Naoki Iwashita1,2, Yoshiichi Takagi1,3, Atsushi Miyasaka4, Masayo Kushiro5, Shiro Miyake6, Tomoki Fukuyama7.   

Abstract

Deoxynivalenol (DON) contamination in food is a public health concern; however, the effect of DON exposure on immune disorders including allergies remains unclear. The aim of this study is to elucidate the effect of oral exposure to DON on pro-inflammatory and pro-pruritic responses in a mouse model of allergic dermatitis, which was generated by topical application of toluene-2,4-diisocyanate (TDI), a hapten that induces type-2 helper T cells. To evaluate acute exposure to DON, the mice were orally administered vehicle alone, 0.1 mg/kg DON, or 0.3 mg/kg DON 48, 24, and 1 h before the final challenge with TDI. To study subacute exposure, the mice were fed DON-contaminated rodent diet (0.3 ppm) during the experimental period. After the itch behavior and ear-swelling response were monitored, the serum, auricular lymph node, and skin tissue were collected for analyzing immunocyte differentiation, cytokine determination, and histological changes. Acute oral administration of DON significantly enhanced pro-inflammatory responses including ear-swelling response, immunocyte infiltration, and cytokine productions. Histological evaluation supported the occurrence of pro-inflammatory responses. In contrast, acute DON exposure only slightly increased itch behavior. Subacute oral exposure to DON significantly up-regulated the inflammatory responses, but showed almost no effect on pruritic response. In vitro evaluation in dendritic cells and keratinocytes indicated that DON pre-exposure induced a dose-dependent significant increase in cytokine production. Our results imply that both acute and subacute exposures to DON are associated with pro-inflammatory responses in cutaneous allergy.

Entities:  

Keywords:  Allergic dermatitis; Balb/c mouse; Dendritic cells; Deoxynivalenol; Keratinocytes; Th2 cells

Mesh:

Substances:

Year:  2020        PMID: 32813090     DOI: 10.1007/s00204-020-02875-3

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  29 in total

1.  Development of an in vitro skin sensitization test using human cell lines: the human Cell Line Activation Test (h-CLAT). I. Optimization of the h-CLAT protocol.

Authors:  T Ashikaga; Y Yoshida; M Hirota; K Yoneyama; H Itagaki; H Sakaguchi; M Miyazawa; Y Ito; H Suzuki; H Toyoda
Journal:  Toxicol In Vitro       Date:  2005-11-28       Impact factor: 3.500

2.  Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.

Authors:  Tomoki Fukuyama; Sarah Ehling; Elizabeth Cook; Wolfgang Bäumer
Journal:  J Pharmacol Exp Ther       Date:  2015-07-09       Impact factor: 4.030

Review 3.  Interleukin-33 in health and disease.

Authors:  Foo Yew Liew; Jean-Philippe Girard; Heth Roderick Turnquist
Journal:  Nat Rev Immunol       Date:  2016-09-19       Impact factor: 53.106

Review 4.  IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy.

Authors:  Corinne Cayrol; Jean-Philippe Girard
Journal:  Curr Opin Immunol       Date:  2014-09-29       Impact factor: 7.486

5.  Filaggrin knockdown and Toll-like receptor 3 (TLR3) stimulation enhanced the production of thymic stromal lymphopoietin (TSLP) from epidermal layers.

Authors:  Kyung Ho Lee; Kyung-Ah Cho; Ji-Yoon Kim; Jin-Young Kim; Ji-Hae Baek; So-Youn Woo; Jin-Woo Kim
Journal:  Exp Dermatol       Date:  2011-02       Impact factor: 3.960

6.  Subacute oral administration of folic acid elicits anti-inflammatory response in a mouse model of allergic dermatitis.

Authors:  Emi Makino; Tomoki Fukuyama; Yuko Watanabe; Risako Tajiki-Nishino; Hitoshi Tajima; Aya Ohnuma-Koyama; Naofumi Takahashi; Ryoichi Ohtsuka; Yoshimasa Okazaki
Journal:  J Nutr Biochem       Date:  2019-01-26       Impact factor: 6.048

7.  Induction of suppressors of cytokine signaling by the trichothecene deoxynivalenol in the mouse.

Authors:  Chidozie J Amuzie; Junko Shinozuka; James J Pestka
Journal:  Toxicol Sci       Date:  2009-07-22       Impact factor: 4.849

8.  The mycotoxin deoxynivalenol facilitates allergic sensitization to whey in mice.

Authors:  M Bol-Schoenmakers; S Braber; P Akbari; P de Graaff; M van Roest; L Kruijssen; J J Smit; B C A M van Esch; P V Jeurink; J Garssen; J Fink-Gremmels; R H H Pieters
Journal:  Mucosal Immunol       Date:  2016-02-17       Impact factor: 7.313

9.  The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses.

Authors:  Bryan D Bell; Masayuki Kitajima; Ryan P Larson; Thomas A Stoklasek; Kristen Dang; Kazuhito Sakamoto; Kay-Uwe Wagner; Daniel H Kaplan; Boris Reizis; Lothar Hennighausen; Steven F Ziegler
Journal:  Nat Immunol       Date:  2013-02-24       Impact factor: 25.606

Review 10.  Recent advances in atopic dermatitis.

Authors:  Kangmo Ahn; Byung Eui Kim; Jihyun Kim; Donald Ym Leung
Journal:  Curr Opin Immunol       Date:  2020-04-13       Impact factor: 7.486

View more
  2 in total

1.  Deoxynivalenol induces caspase-3/GSDME-dependent pyroptosis and inflammation in mouse liver and HepaRG cells.

Authors:  Xiaoxiao Mao; Jie Li; Xin Xie; Shuang Chen; Qiang Huang; Peiqiang Mu; Jun Jiang; Yiqun Deng
Journal:  Arch Toxicol       Date:  2022-08-04       Impact factor: 6.168

2.  Exploring the dermotoxicity of the mycotoxin deoxynivalenol: combined morphologic and proteomic profiling of human epidermal cells reveals alteration of lipid biosynthesis machinery and membrane structural integrity relevant for skin barrier function.

Authors:  Giorgia Del Favero; Lukas Janker; Benjamin Neuditschko; Julia Hohenbichler; Endre Kiss; Lydia Woelflingseder; Christopher Gerner; Doris Marko
Journal:  Arch Toxicol       Date:  2021-04-23       Impact factor: 5.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.